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ABSTRACT 
The pandemic of coronavirus disease 2019 (COVID-19) caused by the severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more 
than 2 million people worldwide with case fatality rates between 3-15%. The 
pathophysiology of this newly emerging disease in affecting cardiovascular 
system is poorly understood. This review aimed to understand from various 
retrospective studies and case reports that have been published and updated 
during the pandemic of COVID-19 related to the underlying mechanism and 
cardiovascular interaction with coronavirus. A literature search was done with 
Google search, PubMed, European Society of Cardiology (ESC) and Journal of 
American Medical Association (JAMA) network since the early days of COVID-19 
pandemic. Clinical presentation may be asymptomatic or the severe cases will 
have acute respiratory distress syndrome (ARDS). Protein spikes of SARS-CoV-2 
virus use the angiotensin-converting enzyme 2 (ACE2) as viral entry to host cells. 
Due to the upregulation of ACE2, people with any pre-existing cardiac diseases 
are more vulnerable to the infection and more likely to have a severe condition 
of COVID-19 infection with a higher risk of mortality. On the other hand, ACE2 
has protective effects against myocardial inflammation and lung injuries. 
Several cases of COVID-19 infection may have cardiac manifestations as a chief 
complaint or acute cardiac injury as the complication. Recent case reports show 
that acute cardiac injury, myocarditis, cardiogenic shock, thromboembolism, 
and arrhythmias could be the complications of COVID-19 even without history 
or risk factors of cardiovascular disease. There are several hypotheses related 
to the mechanism of acute cardiac injury in COVID-19 patients, including 
damage through ACE2 receptors, hypoxia, cardiac microvascular damage, and 
inflammatory response.COVID-19 infection can cause many interactions in the 
cardiovascular system, whether the patients already had chronic heart disease 
or not. Considering the lack of evidence of the RAS inhibitor in COVID-19, the 
use of ACE inhibitor/ARB should be continued unless contraindicated and may 
be beneficial in patients with hypertension, heart failure and diabetes mellitus. 
Early recognition of cardiac manifestations from COVID-19 infections will be the 
key to prevent short and long term cardiac adverse events. 
ABSTRAK
Pandemi penyakit coronavirus disease 2019(COVID-19) yang disebabkan 
oleh severe Acute respiratory syndrome coronavirus 2(SARS-CoV-2) telah 
menginfeksi lebih dari 2 juta orang di seluruh dunia dengan tingkat fatalitas 
antara 3-15%. Pemahaman terhadap patofisiologi penyakit baru ini terhadap 
sistem kardiovaskular masih kurang. Tinjauan pustaka ini bertujuan untuk 
memahamimekanisme yang mendasari dan interaksi kardiovaskular dengan 
virus corona dari berbagai studi retrospektif dan laporan kasus yang terbitpada 
masa pandemik COVID-19 Pencarian pustaka menggunakan Google Search, 
PubMed, European Society of Cardiology (ESC), dan jejaring Journal of American 
Medical Association (JAMA) dimulai sejak awal masa pandemi COVID-19.
Presentasi klinis dapat berupa kasus asimtomatik atau sampai berat yang 
memiliki sindrom gangguan pernapasan akut (ARDS). Protein perrmukaan S 
SARS-CoV-2 menggunakan reseptor enzim pengkonversi angiotensin 2 (ACE2) 
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sebagai pintu masuk ke sel inang. Karena terjadi peningkatan reseptor ACE2 
pada pasien dengan riwayat penyakit jantung sehingga lebih rentan teinfeksi 
dan lebih memiliki risikokeparahan sampai kematian lebih tinggi bila terinfeksi 
COVID-19. Di sisi lain, reseptor ACE2 memiliki efek protektif terhadap peradangan 
miokard dan cedera paru. Beberapa kasus infeksi COVID-19 mungkin memiliki 
manifestasi jantung sebagai keluhan utama atau cedera jantung akut sebagai 
komplikasi. Laporan kasus terbaru menunjukkan bahwa cedera jantung 
akut, miokarditis, syok kardiogenik, tromboemboli, dan aritmia bisa menjadi 
komplikasi pada pasien COVID-19 bahkan pada pasien tanpa riwayat atau faktor 
risiko penyakit kardiovaskular. Ada beberapa hipotesis yang terkait dengan 
mekanisme cedera jantung akut pada pasien COVID-19, antara lain kerusakan 
melalui reseptor ACE2, hipoksia, kerusakan mikrovaskuler jantung, dan respon 
inflamasi. COVID-19 dapat menyebabkan interaksi dengan sistem kardiovaskular 
baik pada pasien yang memiliki riwayat penyakit kardiovaskular sebelumnya 
maupun tidak. Mengingat kurangnya bukti dari inhibitor RAS di COVID-19, 
penggunaan angiotensin converting enzyme inhibitor (ACEi)/angiotensin receptor 
blocker (ARB) harus dilanjutkan kecuali terdapat kontraindikasi dan mungkin 
bermanfaat pada pasien dengan hipertensi, gagal jantung dan diabetes melitus. 
Deteksi dini manifestasi jantung dari infeksi COVID-19 menjadi kunci mencegah 
efek samping jantung jangka pendek dan panjang.
INTRODUCTION
The outbreak of acute respiratory 
tract infections started since December 
2019 in Wuhan, Hubei Province in China 
caused by the 2019-novel coronavirus 
(2019-nCov) is still a global health 
problem.1 This infectious disease which is 
now referred as coronavirus disease-2019 
(COVID-19) is caused by the severe acute 
respiratory syndrome coronavirus 2 
(SARS-CoV-2).2 On the 11th of March 2020, 
the World Health Organization (WHO) 
declared COVID-19 as a pandemic with 
the number of cases globally already 
exceeding more than 5,000,000 cases 
and mortality rates exceeding 350,000 
cases. The number of cases in Indonesia 
has exceeded 25,000confirmed cases and 
mortality rates of more than 1500 cases 
at the end of May 2020 while the number 
of cases continues to increase every day.3
Coronavirus infections in humans 
are generally relatively mild, but 
the epidemic of the previous beta 
coronaviruses, severe acute respiratory 
syndrome coronavirus (SARS-CoV) 
and Middle East respiratory syndrome 
coronavirus (MERS-CoV) caused more 
than 10,000 cumulative cases in the 
last 2 decades with case fatality rates 
(CFR) of 10% for SARS-CoV and 37% for 
MERS-CoV.4Overall the total case fatality 
rate (CFR) in China reached 2.3%, with 
80% of patients infected with COVID-19 
experiencing symptoms of mild and 
cured without intensive medical 
intervention. However, some case 
reports reported morbidity and mortality 
rates were significantly increased at 
the age above 70 years (14.8%) and for 
patients with comorbidities such as 
hypertension (6%), diabetes mellitus 
(7.3%) and cardiovascular diseases 
(10.5%).This number is higher than that 
of the average CFR on the population 
without any comorbidity.5
Clinical manifestations in COVID-19 
infections are generally dominated by 
pulmonary symptoms, but some patients 
experience severe cardiovascular 
damage.Cardiovascular comorbidity 
can also increase mortality.6Previous 
literature review of extra-pulmonary 
complications related to influenza 
infections including SARS-CoV showed 
that there is a clinical entity with viral 
myocarditis, cardiovascular events, with 
increases of hospitalization and deaths 
during epidemic periods.7 Experience 
from emergency visits in New York City 
estimates there was also an increase 
in cardiovascular mortality during 
seasonal influenza infection.8
Acute and chronic cardiovascular 
complications of pneumonia often 
occurring and are the result of multiple 
mechanisms among other factors 
122
Herman H, et al, Clinical cardiac manifestations...
including relative ischemia, systemic 
inflammation and pathogen-related 
damages. This COVID-19 outbreak 
underscores our needs to develop a 
deeper understanding of the implications 
of viral infections on both the short and 
long-term cardiovascular system.9 The 
pathophysiology of this newly emerging 
disease in affecting cardiovascular 
system is poorly understood. This review 
aimed to give an understanding from 
various retrospective studies and case 
reports that have been published and 
updated during the pandemic of COVID-19 
related to the underlying mechanism 
and cardiovascular interaction with 
coronavirus. Furthermore, we want to 
look for the short-term and long-term 
effect of this viral infection to cardiac 
complication.
MATERIALS AND METHODS
A literature search was done with 
Google search, PubMed, European 
Society of Cardiology (ESC) and Journal 
of American Medical Association (JAMA) 
network since the early days of COVID-19 
pandemic. Search terms of ‘COVID-19’, 
‘coronavirus’, ‘SARS-CoV-2’, ‘acute cardiac 
injury’, ‘ACE inhibitor’, ‘ACE2 receptor’, 
‘myocarditis’, ‘cardiac manifestation’, 
‘arrhythmia’, and ‘cardiogenic shock’ 
was used in combination for literature 
searching. Other than that, we also went 
through the article’s reference from the 
relevant literature.The article published 
in other than English language was 
excluded from this review. We reviewed 
articles consist of retrospective study, 
cohort, case report/series from different 
part of the world that has been affected 
with COVID-19. The population of the 
studies consist of patients that treated in-
hospital from mild to severe cases.
RESULT
Pathogenesis of COVID-19
FIGURE 1. Schematic figure describing the role of Angiotensin-Converting 
Enzyme (ACE) in Coronavirus Disease 2019 (COVID-19) infection 
related to viral infection into the lungs. The ACE2 act as the entry 
receptors of the virus to the host cell, and its number may be 
upregulated due to the chronic use of Angiotensin-converting 
enzyme inhibitor (ACEi) or Angiotensin Receptor Blockers 
(ARB). This condition may cause the increased viral load. On 
the other hand, the high level of ACE2 and the use of ACEi/ARB 
may have some protective effects by increased production of 
Ang 1-7 that has vasodilatory and anti-inflamatory effects, 
preventing further lung injury and cardiac damage (16, with 
permission from Oxford University Press Journal)
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Coronavirus (CoV) is a family of 
single-stranded RNA viruses that can 
infect both animals and humans, causing 
respiratory diseases, and problems with 
gastrointestinal tract, kidneys, liver 
and nerves.10 Coronavirus is a corona-β 
enveloped non-segmented positive-sense 
single-stranded RNA part of the family 
Coronaviridae and order Nidovirales.4 
Transmission methods that have been 
researched indicate that the main 
transmission line is through respiratory 
droplets either via airborne or direct-
contact. Recent case report shows that 
there is a possibility of viruses can 
be transmitted through the feces-oral 
route as well as the transmission to 
fetus in pregnant women.10 SARS-CoV-2 
compared to SARS-CoV and MERS-CoV 
has a faster transmission speed with a 
longer incubation period of 2-14 (mean 
5.2) days. The peak season is the same 
as SARS-CoV in the winter between 
December and January, while MERS-CoV 
typically occurs in the summer between 
May-July.11
The structure of the SARS-CoV-2 virus, 
measuring between 26-32 kilobases (kb), 
is one of the largest viral genomes. The 
virion has a nucleocapsid consisting of 
a genomic RNA and a phosphorylated 
nucleocapsid protein (N), which is located 
in phospholipid bilayered membranes. 
Membrane phospholipids are coated 
with two different types of spike protein 
structure namely trimmer glycoprotein 
(S) and hemagglutinin-esterase (HE). 
Membrane proteins (M) and envelope 
(E) are located between the S proteins 
in the virus wrapper.12 There are many 
similarities found from the 3-dimensional 
computer model that shows the protein 
spike structure between SARS-CoV-2 
with SARS-CoV is almost identical to that 
of the receptor areas that maintain van 
der Waals forces.13
The protein spike has a strong 
binding affinity towards angiotensin-
converting enzyme 2 (ACE2) receptor 
in humans based on the analysis of 
biochemical and structural interaction. 
ACE2 is an integral glycoprotein of the 
type 1 cell membrane which is expressed 
and active in many human tissues. The 
highest expression of ACE2 is observed 
in the lungs, endothelium, intestines, 
kidneys and heart. The lungs are more 
susceptible to infection than other target 
organs due to the large area of the lung 
surface and 83% of the cells expressing 
ACE2 are alveoli cell epithelium type 2.13
ACE2 is known to be a functional 
receptor for SARS-CoV-2 and SARS-
CoV viruses to initiate the process of 
infection by making a bond between the 
protein spike in the viruses with ACE2 
receptors.6 As mentioned before, SARS-
CoV-2 has similarities with the previous 
SARS-CoV virus, and this similarity is 
critical from previous research on SARS-
CoV. An autopsy on animal models and 
humans showed SARS-CoV suppresses 
ACE2 pathways in the myocardium 
and lungs, thereby causing myocardial 
inflammation, pulmonary edema and 
acute respiratory failure.9 Injecting 
SARS-CoV spikes into mice models 
demonstrated the critical steps of viral 
entry into the host cells because the 
RAAS system was blocked by attenuated 
ACE2 expression leading to lung injury. It 
shows that ACE2 is not only acting as an 
entry receptor but also protects against 
lung injury.13
The ACE2 receptors have an 
important role in the cardiovascular and 
immune systems. Angiotensin II in the 
renin-angiotensin system (RAS) is the 
main substrate for the ACE2 receptors.14 
The ACE2 receptors catalyze the 
changes of angiotensin II to angiotensin 
1-7, which serve as vasodilators and 
create the effect of protection to the 
cardiovascular system. In the study 
with animal models, there is a link to 
the introduction of ACE inhibitor (ACEi) 
and angiotensin receptors blocker (ARB) 
with increased expression and activity of 
the ACE2 in various organs including the 
heart. The secretion of ACE2 in urine is 
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also increased in hypertensive patients 
treated with ARB, which signifies an 
increase in the number of ACE2 receptors 
in a patient’s cells with ARB therapy.15,16
COVID-19 in patients with 
cardiovascular disease 
Respiratory symptoms appear to be 
heavier in patients with cardiovascular 
disease, where hypotheses to date 
associate this respiratory distress or 
dyspnea with increased ACE2 excretion 
compared to healthy individuals. The 
number of ACE2 receptors can be 
increased by the use of ACEi/ARB.6The 
evidence related to ACEi and ARB therapy 
in patients with or without pre-existing 
cardiac conditions in the COVID-19 
pandemic period is still debatable. There 
are two main hypotheses regarding the 
inhibition of the RAS.17
The first possible mechanism shows 
the use of RAS inhibitors will increase 
the ACE2 level, which is the binding 
site for SARS-CoV-2. On the other hand, 
the other possibilities show that the 
viral infection will cause lung injury 
and decreased expression of ACE2. The 
use of ACE inhibitors will diminish the 
production of angiotensin II, while ARB 
will block the action of angiotensin 
II and AT1 receptors, which leads to 
enhanced generation of angiotensin 
1-7, which attenuate inflammation and 
fibrosis and play protective roles in the 
cardiovascular system.17
Meanwhile, the upregulation of 
ACE2 by RAS inhibitor will increase the 
anti-inflammatory and anti-oxidative 
effects which may be beneficial to 
prevent lung injury. Professional 
societies of cardiovascular disease and 
hypertension in Europe and America 
recommend to continue the use of ACE 
inhibitor/ARB in COVID-19 patients 
unless clinically indicated but they 
do not suggest initiation of the drugs 
unless patients have hypertension, heart 
failure or diabetes mellitus.18 Abrupt 
withdrawal from these drugs may cause 
clinical instability and adverse health 
outcome in patients with pre-existing 
cardiovascular diseases.19
Experiments related to ACE2 
expression in the human heart showed 
that there was low expression of ACE2 
in cardiomyocytes compared to the 
intestines, testis and kidneys, although 
ACE2 was highly expressed in pericytes 
that spread outside the endothelial cells 
of capillary and venules. The SARS-
CoV-2 infection may attack the pericytes 
and cause endothelial cell dysfunction 
which may explain the microcirculation 
disorders in the human heart.20
There are some speculation about 
favorable conditions of pulmonary 
hypertension (PH) in COVID-19 infection. 
Reports from the researchers and 
clinicians of PH found that only 13 
patients with PH were infected with 
COVID-19 and only 1 patient died. 
There is a biological plausibility that 
this may be because of a PH specific 
mediation such as endothelin receptor 
antagonist, phosphodiesterase-5 (PDE-
5), nitrite oxide and prostacyclin which 
had protective effects. Endothelin 
receptor antagonists may inhibit 
angiotensin II, and in the process, the 
layers of the pulmonary endothelial 
cells show microvascular inflammation 
of endothelium hypothetically may 
interrupt the cytokine sudden releases 
syndrome, now known as the ‘cytokine 
storm’.21
Cardiac manifestations
Cardiovascular complications in an 
influenza viral outbreak can generally 
be categorized as myocardial, acute 
myocardial infarction, and cardiac 
failure. As observed in the previous 
influenza season, it can contribute to 
increased mortality in patients over 
65 years of age, especially in patients 
with coronary heart disease.8 When 
compared to SARS-CoV infection which 
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has cardiac manifestations such as 
an increase of sympathetic activities, 
cardiac arrest and sub-clinical diastolic 
disorder, and MERS-CoV with acute 
myocardial manifestations and acute 
heart failure, a recent study of cardiac 
manifestations in patients COVID-19 
shows the manifestation of cardiac acute 
cardiac injury, shock and arrhythmia.9
FIGURE 2. Cardiovascular manifestation and hypothetical mechanism 
in SARS-CoV-2 infection. Started with the penetration of 
coronavirus to host cells including type 2 pneumocytes, 
macrophages, endothelial cells, pericytes, and cardiac myocytes 
leads to severe microvascular and macrovascular dysfunction. 
In respiratory tract infection, SARS-CoV-2 infection could lead 
to ‘cytokine storm’ which is possible to activate T cells and 
macrophage then infiltrate myocardium resulting in severe 
cardiac damage such as myocarditis, plaque instability/rupture. 
That mechanism may cause the acute coronary syndrome, 
heart failure and arrhythmia (28, with permission from Oxford 
University Press Journal).
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COVID-19 patients with 
cardiovascular comorbidities are more 
likely to develop acute cardiac injury 
and heart failure. Death from cardiac 
complications are not only found in 
patients with cardiovascular diseases 
but also patients without any previous 
cardiovascular conditions. This signifies 
that the high risk of death caused by 
cardiac complications has not been said 
solely due to the pre-existing conditions 
of cardiovascular disease. Although 
cardiovascular disease characteristics 
such as chronic hypertension are more 
commonly found in deceased patients.22 
Patients with underlying cardiovascular 
and metabolic diseases also have a 2-fold 
incidence in cases requiring intensive 
care. Meanwhile the patient with acute 
cardiac injury has a 13-fold incidence in 
the case of intensive treatment.23
The severity of primary respiratory 
syndrome also increases the risk of 
complications in patients with a history 
of cardiovascular diseases.9 Sometimes, 
patients have presented with chest pain 
complaints such as typical angina and 
palpitations without any respiratory 
symptoms but are confirmed with 
COVID-19. Among the patients without 
the previous cardiovascular disease, 
there are patients who experienced 
significant heart failure, with increased 
heart enzymes troponin I or cardiac 
arrest during hospital treatment.6
Liu et al.,1 reported that COVID-19 
patients with cardiac manifestations 
(58.5%) have lower baseline value of 
lymphocytes, (0.99 ± 0.43) x10µ/L, throat 
swab showing more than one positive 
nucleic acid (50%), and more oxygen 
supplementation required (79%) when 
compared to the group without cardiac 
manifestations. However, multivariate 
analysis using logistic regression 
model suggests that cardiovascular 
manifestations are not an independent 
predictor of hospital adverse events. 
Sudden cardiac arrest can occur as a 
result of prolonged sedentary hypoxia 
causing myocardial suppression . 
Infection of COVID-19 may be divided 
into 3 stages, consisting of mild, moderate 
and severe stages. The early infection is 
associated with mild and non-specific 
systemic symptoms, and prognosis and 
recovery are excellent. Some patients 
may progress to the moderate stage with 
pulmonary involvement with or without 
hypoxia. A minority of patients will 
develop the severe stage with systemic 
hyper-inflammation which manifests 
as an extra-pulmonary syndrome. In 
this stage, systemic hyper-inflammation 
may increase cardiac biomarkers such 
as Troponin and N-terminal pro-B-
type natriuretic peptide (NT-proBNP) 
as the signs of acute cardiac injury or 
myocarditis.24
Acute cardiac injury
Acute cardiac injury related to viral 
infection was reported in 5 of 41 patients 
in China treated with COVID-19, and 
had high sensitive-cardiac troponin 
I (HS-cTnI) value increased over 99 
normal value percentiles.4   Research 
on  41 medical officers in China with 
an average age of 39 years old infected 
with COVID-19 found they experienced 
acute cardiac injury characterized 
by the increase of HS-cTnI above 
the value of 99 percentile, or new 
abnormalities in electrocardiogram and 
echocardiography during the period of 
COVID-19 infections.1 A total of 23% of 
52 patients with COVID-19 who were 
critically ill had also experienced acute 
cardiac injury.25 Meanwhile, Shi et al.26 
reported that patients with an underlying 
cardiac disease were more likely to 
develop an acute cardiac injury, and it 
is significantly and clinically associated 
with higher risk of in-hospital mortality.
There are several hypotheses related 
to the mechanism of acute cardiac injury 
in patients with Coronavirus infection, 
including damage of ACE2 receptors, 
hypoxia, cardiac microvascular 
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damage, and inflammatory response. 
Increased affinity to ACE2 receptors 
and decreased expression count from 
ACE2 is considered the source of the 
occurrence of dysregulation in the RAS 
system. Severe damage to the state of the 
lung leads to oxidative stress that causes 
an intra-cell acidosis and mitochondrial 
damage. In conditions like the viral 
myocarditis, a microvascular breakdown 
occurs which causes a disruption of the 
fusions into myocardial. In the condition 
of the systemic inflammatory response 
is the occurrence of the ‘cytokine storm’ 
and disruption of the immune system 
that causes uncontrolled inflammation.6
Pathological changes in myocardial 
tissue can occur due to viral replication 
directly in myocardial or indirect 
through the systemic inflammatory 
response as a response to breath failure 
or an unexpected immune response due 
to viral infections. Inflammation of the 
myocardial and symptoms associated 
with the suppression of the ACE2 system 
can lead to myocardial dysfunction 
and cardiac complications. Consensus 
experts in China indicate immediate 
damage to the cardiac structure occurs 
more often in neonates, whereas in 
adults the immunogenic damage is a 
major factor.27
The reversibility condition of the 
cardiac structure and function without 
significant decline after the cure of 
the COVID-19 virus makes it possible 
that besides the mechanisms of viral 
replication in the myocardium, the 
immune response or ‘cytokine storm’ 
can also be an important mechanism. 
The ‘cytokine storm’ is a phenomenon 
involving the production of a wide 
range of cytokines in massive and rapid 
levels of body fluids after infected with a 
microorganism. It is an important cause 
of acute respiratory failure and multiple 
organ dysfunction. Interestingly, these 
cytokine storms can improve vascular 
wall permeability and myocardial 
edema, which explains the occurrence of 
thickening of the heart walls in patients 
with myocarditis and it can potentially 
destabilize atherosclerotic plaques that 
may cause acute coronary syndrome 
(ACS).27,28 There’s lack of study regarding 
the incidence of ACS in COVID-19, but in 
viral infection, we should consider the 
myocardial infarction type 2, because 
of mismatch perfusion and demand in 
the myocardium, was the most common 
subtype of ACS.28,29
Myocarditis
A case report from Sichuan, China 
described the case of a male patient aged 
37 years with chest pain and tightness 
complaints since three days before 
admission accompanied by diarrhea, with 
a clinical presentation of hypotension. 
The supporting examination obtained 
cardiac enlargement and an ECG 
image leading to acute myocardial 
infarction of ST-segment (IMA-EST) 
inferiorly, supported by an increase in 
heart enzymes Troponin T more than 
10,000 ng/L and NT Pro BNP 21.025 
ng/L. Echocardiography test showed 
decreased fraction ejection (27%) and 
minimal pericardial effusion. A CT-
scan coronary emergence examination 
was conducted and obtained normal 
coronary arteries results. After the 
result of the SARS-CoV-2 virus acid 
test was positive, the patient was then 
diagnosed as fulminant myocarditis with 
cardiogenic shock caused by COVID-19. 
After therapy with early glucocorticoids 
and human immunoglobulin the patient 
improved, and the evaluation of the 
heart dimensions returned to normal.30 
The wide QRS, atrioventricular block, 
tachycardia or ventricular fibrillation 
raises the risk of death in the hospital in 
patients with myocarditis.29
Examination of anatomical 
pathology in cardiac cells in patients 
aged 50 years in China with the ARDS and 
sudden cardiac death, only found slightly 
infiltrated mononuclear inflammatory 
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cells without any substantial myocardial 
tissue damage. Meanwhile from lung 
cell biopsies, there is desquamation of 
pneumocytes, the formation of hyaline 
membranes and pulmonary edema that 
supported the image of ARDS.31 These 
results indicate the possibility that 
COVID-19 might not directly impair the 
heart.26
Sala et al.,32 reported the case of 43 
year old woman in Italy, who presented 
with chest pain and dyspnea. Her chest 
x-ray documented subtle bilateral 
opacities, and she was confirmed with 
SARS-CoV-2 positivity. The first clinical 
suspicion from ECG, cardiac biomarker 
and echocardiography was myocarditis. 
But, the dynamic 3D volume-rendering 
reconstruction of Cardiac CT-Scan 
demonstrated hypokinesia at the basal 
and mid-segment of the left ventricle with 
normal apical contraction suggesting 
a reverse Tako-Tsubo Syndrome (TTS). 
Then, the endomyocardial biopsy 
found an absence of viral infiltration in 
myocardium with diffuse T-lymphocytic 
inflammatory infiltrates. The final 
diagnosis was acute virus-negative 
lymphocytic myocarditis associated with 
SARS-CoV-2 respiratory infection.
Myocarditis is established with the 
gold standard of biopsy, immunology, 
or immunochemical examinations. 
The diagnosis of myocarditis has some 
challenges because the initial clinical 
presentation that appears more often 
leads to a typical chest pain of angina 
or acute heart failure. Supporting 
examinations such as cardiac magnetic 
resonance imaging (CMR) can be 
performed to help direct the diagnosis of 
clinically myocarditis suspicion.33
Cardiogenic shock
A case report from the UK mentions 
a female patient case, 47 years with a 
major complaint of fever, shortness of 
breath and chest pain, without a history 
of previous cardiovascular risk factors. 
Clinical symptoms with were unstable 
hemodynamics hypotension and 
tachycardia. ECG indicated the presence 
of ST elevation in the inferior-lateral, chest 
X-rays showing mild pulmonary edema. 
The patient once performed angiography 
three years earlier with normal coronary 
artery. Echocardiography indicated 
the presence of medium-pericardial 
effusion. She waas hospitalized in the 
intensive cardiac care ward. Throat 
swab results confirmed the COVID-19 
diagnosis. During the clinical treatment 
of the patient she deteriorated, and 
echocardiography evaluation showed 
a circumferential 2-cm pericardial 
effusion with cardiac tamponade. Finally, 
in the emergency treatment, there were 
serohemorrhagic fluid and negative test 
results for COVID-19.34
During the COVID-19 pandemic, 
the Chinese used the criteria of expert 
consensus to diagnose fulminated 
myocarditis. Fulminant myocarditis 
is a clinical diagnosis of myocardial 
inflammatory disease, accompanied 
by severe hemodynamic rapid 
deterioration. Accompanying signs and 
symptoms include sudden attacks, a 
clear history of viral infections, rapid 
and severe hemodynamic dysfunction, 
myocardial injury and a decrease in 
diffuse ventricular wall kinetics.35
Arrhythmia
As previously mentioned above, 
viral infection can cause inflammation 
of myocardium, metabolic dysfunction 
and activation of sympathetic nervous 
system, that one of combination of this 
risk could precipitate an arrhythmia.29 In 
critical ill patient, electrolyte imbalances 
can occur especially in a patient with 
cardiovascular comorbidity and may 
precipitate arrhythmia. One of the 
common electrolyte imbalance was 
hypokalemia. Hypokalemia caused by 
the effect of RAA system to retain water 
and sodium while excreted potassium. 
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Moreover, in SARS-CoV-2 infection, the 
ACE2 receptor function was altered and 
some patients may develop diarrhea 
as complication making the risk of 
hypokalemia even higher.35,36
Some drugs have been widely 
used in clinical practice as the trial 
for COVID-19 therapy but some of the 
drugs have been stated to possibly 
cause arrhythmia by prolonging QT 
intervals. The use of immunomodulatory 
drugs such as chloroquine (CQ) and 
hydroxychloroquine (HCQ) is assessed 
to be a therapy for COVID-19 infections. 
There have been no case reports of 
ventricular arrhythmias caused by 
quinine therapy in COVID-19 patients.37 
Previous research in patients with 
malaria given chloroquine therapy 
has identified the risk of QT interval 
extension and increased risk of Torsade 
de Pointes (TdP). Monitoring of QT 
interval needs to be done in patients who 
received chloroquine therapy.38
From the large scale case-control study 
of azithromycin, there were increases of 
ventricular arrhythmia compared to the 
patients with no antibiotic, but the risk 
became insignificant when comparing 
azithromycin with amoxycillin.37 
Strategies for minimizing the risk of 
arrhythmias by monitoring the baseline 
QT corrected (QTc) intervals indicated 
if patients had QTc more than 500 msec 
or known congenital Long QT syndrome 
there is a preference to withhold the 
drugs that prolonged QT intervals. It is 
important the intervals are normalized 
if the patient had conditions such as 
hypokalemia, hypomagnesemia, fever 
and inflammatory state.40
Thromboembolic events
A case report from Italy mentions 
pulmonary embolism manifestations in a 
female aged 75 years with severe bilateral 
pneumonia, and confirmed diagnosis 
of COVID-19 infection. The patient did 
not have a risk of venous thrombosis, 
and clinically hemodynamically 
stable. Laboratory findings showed 
an increase in leukocytes, C-reactive 
proteins, troponin-I and D-dimer. 
Echocardiographic evaluation indicated 
the presence of severe hypokinetic in 
the right ventricle with a pressure of 
60 mmHg pulmonary artery, while the 
doppler compression ultrasonography 
(CUS) at inferior extremity showed the 
negative result. There was a bilateral 
filling defect that matched signs for 
pulmonary embolism with dominant 
pulmonary consolidation in the posterior 
part of the lung from the CT-scan.41
The animal model of acute respiratory 
distress syndrome (ARDS) which was 
infected with a lethal dose of influenza 
virus demonstrated the increases 
of platelet aggregation, pulmonary 
microvascular thrombosis, endothelial 
damage and hyperinflammatory 
cytokine response. This model shows the 
development of thrombus under highly 
inflammatory conditions. Infection-
mediated thrombosis may be related to 
the inflammatory response induced by 
the pathogen to the coagulation system.42
Short and long-term effects of 
COVID-19 to cardiovascular disease
For the short-term period during 
this pandemic time, many hospitals 
have advised postponing non-critical 
outpatient visits, defer elective cardiac 
procedures and surgeries.This condition 
led to a positive impact on the utilization 
of technology and the development 
of virtual clinics. Home-based cardiac 
rehabilitation with smartphone 
applications or trackers may be one of 
the options for delivering programs. 
In the other hand, the risk of being 
exposed to COVID-19 in the pandemic 
period may cause a delay in a patient 
with cardiac emergencies presented to 
the hospital which likely contributes to 
cardiac mortality and morbidity. For 
the long-term effects, deferred elective 
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diagnostic and therapeutic procedures 
are predicted to cause a significant 
impact after pandemic.28,43
Research on long-term cardiac 
manifestations in patients who have 
recovered from SARS-CoV infection 
showed after 12 years as much as 44% 
of survivors have cardiovascular system 
abnormalities and 66% experience 
hyperlipidemia. They gained an overall 
increase in the concentration of free 
fatty acids, lysophosphatidylcholine, 
lysophosphatidylethanolamine, and 
phosphatidylglycerol in serum samples 
compared to individuals who have never 
been infected with SARS-CoV. Based on 
the consideration that SARS-CoV-2 and 
SARS-CoV have many similarities of 
structure with the novel COVID-19, the 
long-term effect on the cardiovascular 
system in patients recovering from 
COVID-19 needs to be anticipated.6
TABLE 1. Review of cardiac manifestation during COVID-19 pandemic from case re-
ports to retrospective observational studies
First 
Author
Type of Study S a m p l e 
Size
Pre-existing cardiac 
condition
Cardiac Manifestation Outcome
Chen et al22 retrospective 274 34% of patients had 
hypertension, 8% 
had cardiovascular 
disease
77% of deceased patients 
developed acute cardiac 
injury and 49% had heart 
failure
Patients with a history of 
cardiovascular comorbidities 
were more likely to develop 
acute cardiac injury and heart 
failure
Chen et al44 Retrospective 
Cohort
99 40% had 
cardiovascular and 
c e r e b r o v a s c u l a r 
disease
13% of patients had a 
level of creatinine kinase 
increased
11% of patients died, 58% 
remained at the hospital, 31% 
discharged
Guan et al45 retrospective 
cohort
1099 15% had 
hypertension, 2.5% 
had coronary heart 
disease
25% of patients with 
hypertension and 37% 
of patients with CHD 
presented with severe 
condition
14.5% of patients with 
hypertension and 22.2% of 
patients with CHD meet primary 
endpoints ICU care, needs of 
ventilator or death)
Huang et al4 Retrospective 
Cohort 
41 15 % had 
hypertension, 15% 
had cardiovascular 
disease
12% of patients had an 
acute cardiac injury 
elevated troponin level)
80% of patients with an acute 
cardiac injury need ICU care
Hui et al46 retrospective 41 3 patients had 
hypertension, 9 
patient had cardiac-
related chronic 
diseases, 2 patient 
had coronary artery 
disease
elevation of Troponin-I 
level and low epicardial 
adipose tissue EAT) density 
found in severe and critical 
cases as a hallmark of 
acute cardiac injury, 2 
patients developed atrial 
fibrillation
not described
Liu et al1 Retrospective 
Study
41 4.9% hypertension, 
2.4% CAD, 7.3% 
arrhythmia
58.5% had cardiovascular 
manifestation palpitation/
chest pain, the elevation 
of cardiac biomarker, 
new abnormality on ECG 
including STC) 
75% of patients with CVM had 
in-hospital adverse events, but 
CVM wasn’t the independent 
predictors
Liu et al47 retrospective 
cohort
137 9.5% had 
hypertensionm 7.3% 
had cardiovascular 
disease
Patients with underlying 
cardiovascular disease 
often demonstrated 
comorbid heart failure
cardiac outcomes not described
131
J Med Sci, Volume 52, Number 3 (SI), 2020, Juli: 120-137
Ruan et al48 retrospective 
study
150 34.6% had 
hypertension, 19% 
had cardiovascular 
disease
33.8% had cardiac troponin 
increased
Patients with a history of 
cardiovascular disease all died. 
Some patients died of fulminant 
myocarditis
Shi et al26 retrospective 416 30.5% had 
hypertension, 10.6% 
had coronary heart 
disease, 4.1% had 
chronic heart failure
patients with the 
underlying cardiovascular 
disease more likely to 
developed acute cardiac 
injury
51.2% of patients with acute 
cardiac injury dies
Xu et al49 retrospective 
case series
62 8% had hyperten-
sion
92%* had creatinine kinase 
increased *percentage not 
total 100% owing to miss-
ing data)
98%* needed hospital admis-
sion, no deaths
Yang et al25 retrospective 52 10% had chronic 
cardiac disease
23% had an acute cardiac 
injury
40% of patients with underlying 
chronic cardiac disease and 75% 
of patients with acute cardiac 
injury are in the non-survivors’ 
group
Zhang JJ et 
al50
retrospective 140 30% had 
hypertension, 5% 
had coronary heart 
disease, 3.6% had 
arrhythmia
not described not described
Zhou et al51 Retrospective 
Cohort
191 30% hypertension, 
8% CAD
23% had heart failure, 17% 
acute cardiac injury
among 54 non-survivor, 52% 
had heart failure and 59% acute 
cardiac injury
Danzi et al41 Case report 1 no strong 
predisposing 
factors for venous 
thromboembolism
acute pulmonary 
embolism confirmed 
by CT scan, lower 
limb compression 
ultrasonography was 
negative
not described
Fried et al52 case series 3 case 1: hypertension 
and hyperlipidemia; 
case 2: no pre-
existing cardiac 
disease; case 3: 
non-ischemic 
cardiomyopathy, 
atrial fibrillation 
and hypertension; 
case 4: a history of 
a heart transplant 
in 2007 and taking 
immunosuppressive 
mediation
case 1: presenting with 
STEMI with cardiogenic 
shock, non-obstructive 
coronary, work up as 
myopericarditis; case 2: 
ARDS patients developed 
SVT with normal LV 
function; case 3: acute 
decompensated heart 
failure, developed 
polymorphic VT; case 4: 
presented as pneumonia
case 1: patient recovered; 
case 2: patient underwent 
cardioversion and rescued 
with ECMO; case 3: patient still 
intubated; case 4: the patient 
was discharged after 5 days of 
hospitalization
Hu et al30 Case report 1 none Fulminant myocarditis 
presented with STEMI 
inferior with cardiogenic 
shock
clinically improve after therapy 
if glucocorticoid and human 
immunoglobulin
Hua et al34 Case report 1 no cardiovascular 
risk factors
myopericarditis with 
life-threatening cardiac 
tamponade
improvement of hemodynamic 
after pericardiocentesis
Inciardi et 
al53
Case report 1 no pre-existing 
cardiac condition
myocarditis marked 
with increased of cardiac 
biomarker, a decrease of 
LV function and regional 
wall motion abnormality, 
normal coronary arteries
not described
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Kim et al54 Case report 1 not described 21 years old female 
presented with respiratory 
and gastrointestinal 
symptoms. Chest 
X-ray showed cardiac 
enlargement, confirmed 
with CT and MRI as 
myocarditis
not described
Sala et al32 Case report 1 no history of hyper-
tension or cardiac 
disease
presented with chest 
pain and dyspnea, 3D 
volume rendering CT-
scan demonstrated clear 
hypokinesia of the left 
ventricle mid and basal 
segment, suggesting 
reverse Takotsubo 
syndrome, acute virus-
negative myocarditis
The patient was discharged with 
no symptoms
Tavazzi et 
al55
Case report 1 not described cardiogenic shock 
clinically mimicked 
fulminant myocarditis
patients died of septic shock 
after 12 days stabilization 
with VA-ECMO and IABP, 
endomyocardial biopsy 
demonstrated low-grade 
myocardial inflammation 
and viral particles in the 
myocardium suggesting either 
a viraemic phase or migration 
from the lung
Wang et al56 Case series 138 31.2% had 
hypertension, 14.5% 
had cardiovascular 
disease
7.2% had an acute 
cardiac injury, 16.7% had 
arrhythmia, 
80% of patients with acute 
cardiac injury and 69.6% with 
arrhythmia need ICU care
Xu et al31 case report 1 not described Interstitial mononuclear 
inflammatory infiltrates 
from heart biopsy, no heart 
tissue damage
death
Zeng et al27 Case report 1 no history of 
hypertension or 
cardiac disease
fulminant myocarditis Recovered after antiviral and 
mechanical life support
DISCUSSION
Acute cardiac injury marked with 
the increase of cardiac biomarker such 
as troponin-I was the most common 
manifestation that has been found 
several studies of COVID-19. In some 
case reports showed that abnormality 
of ECG and symptom mimicking ACS as 
the presenting complaint of the patient 
with COVID-19 without any pre-existing 
cardiac condition, and later diagnosed 
as myocarditis or fulminant myocarditis 
if accompanied with cardiogenic shock. 
Thromboembolic events may happen 
in a critically ill patient with a severe 
infection of pneumonia because of local 
thrombosis in the pulmonary artery 
caused by the hyperinflammatory 
response. 
Arrhythmia in COVID-19 patients 
may be precipitate of electrolyte 
imbalance due to critically ill patient 
and worsened with the interaction 
with COVID-19 therapy. There is a 
lack of data in the incidence of type 
1 myocardial infection in COVID-19, 
the available evidence still considered 
type 2 myocardial infarction was the 
most common subtype of ACS in viral 
infection. There is a limitation related 
the exact mechanism of the effects from 
SARS-CoV-2 infection on cardiovascular 
system and its long-term effects because 
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of this new emerging disease. Moreover, 
in this outbreak condition is hard to 
obtain data with better level of evidence 
than cohort studies and case reports.
CONCLUSION
Based on published retrospective 
studies and case reports, cardiac 
manifestations may present as the 
chief complaints or comorbidities in 
patients with COVID-19. Clinical signs 
and symptoms are varying from the 
asymptomatic, rise of the cardiac marker, 
acute cardiac injury, worsening of pre-
existing cardiac condition, ischemia, 
heart failure, thromboembolic event, 
arrhythmia, fulminant myocarditis 
to fatal cardiogenic shock. COVID-19 
infection can cause many interactions 
in the cardiovascular system, whether 
the patients already had chronic heart 
disease or not. There are several 
hypotheses related to the mechanisms 
of cardiac manifestation in patients 
with coronavirus infection, including 
damage to ACE2 receptors, hypoxia, 
cardiac microvascular damage, 
electrolyte imbalance, drug interaction 
and increased inflammatory response. 
Considering the lack of evidence of the 
RAS inhibitor in COVID-19, the use of ACE 
inhibitor/ARB should be continued unless 
contraindicated and may be beneficial 
in patients with hypertension, heart 
failure and diabetes mellitus. Because 
of this is a new emerging disease, long 
term studies related to cardiovascular 
manifestation and therapy in COVID-19 
survivors are still needed to give a better 
understanding of the disease.Early 
recognition of cardiac manifestations 
from patients with COVID-19 infection 
will be the key to prevent short and long 
term cardiac adverse events.
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